169 related articles for article (PubMed ID: 37285207)
1. Evolving Mutational Buildup in HIV-1 Protease Shifts Conformational Dynamics to Gain Drug Resistance.
Souffrant M; Yao XQ; Hamelberg D
J Chem Inf Model; 2023 Jun; 63(12):3892-3902. PubMed ID: 37285207
[TBL] [Abstract][Full Text] [Related]
2. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
3. Highly drug-resistant HIV-1 protease reveals decreased intra-subunit interactions due to clusters of mutations.
Kneller DW; Agniswamy J; Harrison RW; Weber IT
FEBS J; 2020 Aug; 287(15):3235-3254. PubMed ID: 31920003
[TBL] [Abstract][Full Text] [Related]
4. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
[TBL] [Abstract][Full Text] [Related]
5. Revertant mutation V48G alters conformational dynamics of highly drug resistant HIV protease PRS17.
Burnaman SH; Kneller DW; Wang YF; Kovalevsky A; Weber IT
J Mol Graph Model; 2021 Nov; 108():108005. PubMed ID: 34419931
[TBL] [Abstract][Full Text] [Related]
6. Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations.
C S V; Tamizhselvi R; Munusami P
J Biomol Struct Dyn; 2019 Jul; 37(10):2608-2626. PubMed ID: 30051758
[TBL] [Abstract][Full Text] [Related]
7. Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors.
Bastys T; Gapsys V; Walter H; Heger E; Doncheva NT; Kaiser R; de Groot BL; Kalinina OV
Retrovirology; 2020 May; 17(1):13. PubMed ID: 32430025
[TBL] [Abstract][Full Text] [Related]
8. Flap-site Fragment Restores Back Wild-type Behaviour in Resistant Form of HIV Protease.
Luchi A; Angelina E; Bogado L; Forli S; Olson A; Peruchena N
Mol Inform; 2018 Dec; 37(12):e1800053. PubMed ID: 30051611
[TBL] [Abstract][Full Text] [Related]
9. Dynamical Network of HIV-1 Protease Mutants Reveals the Mechanism of Drug Resistance and Unhindered Activity.
Appadurai R; Senapati S
Biochemistry; 2016 Mar; 55(10):1529-40. PubMed ID: 26892689
[TBL] [Abstract][Full Text] [Related]
10. Drug Resistance Mechanism of M46I-Mutation-Induced Saquinavir Resistance in HIV-1 Protease Using Molecular Dynamics Simulation and Binding Energy Calculation.
Rana N; Singh AK; Shuaib M; Gupta S; Habiballah MM; Alkhanani MF; Haque S; Reshi MS; Kumar S
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458427
[TBL] [Abstract][Full Text] [Related]
11. Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights.
Chetty S; Bhakat S; Martin AJ; Soliman ME
J Biomol Struct Dyn; 2016; 34(1):135-51. PubMed ID: 25671669
[TBL] [Abstract][Full Text] [Related]
12. Hybrid QM/MM Free-Energy Evaluation of Drug-Resistant Mutational Effect on the Binding of an Inhibitor Indinavir to HIV-1 Protease.
Taguchi M; Oyama R; Kaneso M; Hayashi S
J Chem Inf Model; 2022 Mar; 62(5):1328-1344. PubMed ID: 35212226
[TBL] [Abstract][Full Text] [Related]
13. Protein promiscuity: drug resistance and native functions--HIV-1 case.
Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
[TBL] [Abstract][Full Text] [Related]
14. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
15. Picomolar to Micromolar: Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance.
Henes M; Lockbaum GJ; Kosovrasti K; Leidner F; Nachum GS; Nalivaika EA; Lee SK; Spielvogel E; Zhou S; Swanstrom R; Bolon DNA; Kurt Yilmaz N; Schiffer CA
ACS Chem Biol; 2019 Nov; 14(11):2441-2452. PubMed ID: 31361460
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs.
Perryman AL; Lin JH; McCammon JA
Protein Sci; 2004 Apr; 13(4):1108-23. PubMed ID: 15044738
[TBL] [Abstract][Full Text] [Related]
17. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
18. Molecular Determinants of Epistasis in HIV-1 Protease: Elucidating the Interdependence of L89V and L90M Mutations in Resistance.
Henes M; Kosovrasti K; Lockbaum GJ; Leidner F; Nachum GS; Nalivaika EA; Bolon DNA; Kurt Yilmaz N; Schiffer CA; Whitfield TW
Biochemistry; 2019 Sep; 58(35):3711-3726. PubMed ID: 31386353
[TBL] [Abstract][Full Text] [Related]
19. Exploring molecular mechanism of allosteric inhibitor to relieve drug resistance of multiple mutations in HIV-1 protease by enhanced conformational sampling.
Chen J; Peng C; Wang J; Zhu W
Proteins; 2018 Dec; 86(12):1294-1305. PubMed ID: 30260044
[TBL] [Abstract][Full Text] [Related]
20. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
Su CT; Kwoh CK; Verma CS; Gan SK
J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
